Aquestive Therapeutics, Inc. financial data

Symbol
AQST on Nasdaq
Industry
Pharmaceutical Preparations
Location
30 Technology Drive, Warren, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
MonoSol Rx, Inc. (to 3/27/2008)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 405 % +289%
Quick Ratio 38.4 % +134%
Debt-to-equity -229 % -51.6%
Return On Equity 36.6 % +78.9%
Return On Assets -28.3 % +29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91.1M shares
Common Stock, Shares, Outstanding 91.1M shares +47.8%
Entity Public Float 82.7M USD +200%
Common Stock, Value, Issued 91K USD +46.8%
Weighted Average Number of Shares Outstanding, Basic 90.9M shares +58.5%
Weighted Average Number of Shares Outstanding, Diluted 90.9M shares +58.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 58.4M USD +25.5%
Research and Development Expense 16.2M USD +11.3%
Costs and Expenses 73.6M USD -1.8%
Operating Income (Loss) -15.2M USD +46.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.8M USD -15.4%
Income Tax Expense (Benefit) -39K USD -114%
Net Income (Loss) Attributable to Parent -25.7M USD -13.7%
Earnings Per Share, Basic -0.38 USD/shares +2.56%
Earnings Per Share, Diluted -0.34 USD/shares +20.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 89.9M USD +301%
Inventory, Net 6.97M USD +17.1%
Assets, Current 104M USD +161%
Property, Plant and Equipment, Net 3.92M USD -14.8%
Operating Lease, Right-of-Use Asset 5.44M USD -5.94%
Other Assets, Noncurrent 4.24M USD -22.5%
Assets 118M USD +106%
Accounts Payable, Current 5.7M USD -46.7%
Employee-related Liabilities, Current 2.67M USD -4.75%
Accrued Liabilities, Current 5.67M USD +33.1%
Contract with Customer, Liability, Current 1.05M USD -73.8%
Liabilities, Current 13.9M USD -64.1%
Long-term Debt and Lease Obligation 27.5M USD -17.8%
Contract with Customer, Liability, Noncurrent 21.8M USD -34.3%
Operating Lease, Liability, Noncurrent 5.24M USD -6.63%
Other Liabilities, Noncurrent 2.03M USD +1.05%
Liabilities 153M USD -6.45%
Retained Earnings (Accumulated Deficit) -335M USD -8.33%
Stockholders' Equity Attributable to Parent -35.5M USD +66.7%
Liabilities and Equity 118M USD +106%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -218%
Net Cash Provided by (Used in) Financing Activities 81.7M USD
Net Cash Provided by (Used in) Investing Activities -29K USD -1350%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 91.1M shares +47.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 71.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 89.9M USD +301%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1M USD -31.6%
Deferred Tax Assets, Valuation Allowance 84.1M USD +0.32%
Deferred Tax Assets, Gross 84.7M USD +0.45%
Operating Lease, Liability 5.69M USD -4.43%
Depreciation 950K USD -33.9%
Payments to Acquire Property, Plant, and Equipment 29K USD +1350%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.7M USD -13.7%
Lessee, Operating Lease, Liability, to be Paid 9.67M USD -9.76%
Property, Plant and Equipment, Gross 47.1M USD +0.05%
Operating Lease, Liability, Current 455K USD +31.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32M USD +4.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28M USD +4.39%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.98M USD -16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.35M USD +3.54%
Deferred Tax Assets, Operating Loss Carryforwards 27.1M USD -15.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD +25.3%
Additional Paid in Capital 299M USD +47.9%
Amortization of Intangible Assets 157K USD -6.55%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.82M USD +115%
Interest Expense 9.09M USD +48.9%